WILMINGTON, Del./NEW YORK (Reuters) – German healthcare group Fresenius alleged it uncovered “blatant fraud at the very top level” of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.